Russian lab unveils cancer vaccine release target

Russia's Gamaleya Research Institute announced that patients could begin receiving a new, personalized cancer vaccine within months. The mRNA-based vaccine, designed using individual genetic data, will target malignant tumors.

Director Alexander Gintsburg stated that experimental treatments will start soon in partnership with leading oncology institutions in Moscow. The vaccine, developed since mid-2022, has shown promise in trials and trains the immune system to attack cancer cells.

Regulatory guidelines have been adapted for this individualized treatment. The project has drawn international interest, with potential collaborations from foreign medical institutions.